Regentis Biomaterials Ltd. (RGNT)
Regentis Biomaterials Ltd. operates in the Medical - Instruments & Supplies industry of the Healthcare sector, headquartered in Herzliya, TA, IL. The stock last traded at $0.72, down 14.42% on the session, giving a market capitalisation of $5.0M. Its beta of -0.69 implies it has historically moved less than the broad market.
Regentis Biomaterials Ltd. is a regenerative medicine firm dedicated to crafting innovative solutions for tissue repair, ultimately aiming to enhance patients' health and overall quality of life. The company's primary product in development is GelrinC, a novel, cell-free, ready-to-use hydrogel designed to be solidified into an implant within the knee. This implant serves to address painful knee injuries and mend articular cartilage damage. Regentis Biomaterials leverages its proprietary Gelrin platform, which employs biodegradable hydrogel implants, to develop orthopedic therapies that facilitate the regeneration of compromised or diseased tissues. The company was established in 2004 and operates from its headquarters in Herzliya, Israel.
Regentis Biomaterials Ltd. is most often compared with the following Healthcare names: